Clinical trials: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid…
- Trial name
- DeLLphi-306 (NCT06117774)
- Testing
- Tarlatamab
- Where
- 204 sites in United States, Argentina and 25 more
- Volunteers
- 404 people
- Sponsor
- Amgen
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
The study includes the screening period (from the time the subject signs the informed consent form to no more than 28 days before the first dose, imaging evaluations are allowed within 28 days before the first dose, and 5-14 days…
- Trial name
- NCT06773156
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Limited Stage Small Cell Lung Cancer
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.
- Trial name
- TIGOS-LS (NCT06773910)
- Testing
- BMS-986489, Durvalumab
- Where
- 34 sites in United States
- Volunteers
- 250 people
- Sponsor
- SCRI Development Innovations, LLC
Localized Small Cell Lung Cancer
Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
Observation and Evaluation of the Efficacy and Safety of Adalimumab Combined with Chemotherapy Followed by Radiotherapy or Radiotherapy Alone as First-Line Treatment for Limited-Stage Small Cell Lung Cancer
- Trial name
- NCT07381543
- Testing
- Adebrelimab Induction Therapy Group, Adebrelimab Maintenance Therapy Group
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Peking University Cancer Hospital & Institute
Limited Stage Small Cell Lung Cancer
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy versus placebo in patients with LS-SCLC who had not progressed following Concurrent or Sequential Chemoradiotherapy.
- Trial name
- SURPASS (NCT05623267)
- Testing
- Sugemalimab
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Sun Yat-sen University
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
This study aims to explore the efficacy and safety of immunotherapy (PD-L1 inhibitor) maintenance following high-dose hyperfractionated simultaneous integrated boost radiotherapy concurrent chemotherapy in patients with…
- Trial name
- NCT06869239
- Testing
- Etoposide + cisplatin/carboplatin, Thoracic radiotherapy, Prophylactic cranial irradiation (PCI)
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking University Cancer Hospital & Institute
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.
- Conditions
- Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03811002
- Testing
- 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection
- Where
- 542 sites in United States, Japan
- Volunteers
- 544 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Carcinoma
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
This study plans to enroll limited-stage small cell lung cancer (LS-SCLC) patients who have achieved disease control after concurrent chemoradiotherapy (cCRT).
- Trial name
- NCT07357532
- Testing
- Adebrelimab Injection, Apatinib Mesylate Tablets
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Peking University Cancer Hospital & Institute
Limited Stage Small Cell Lung Cancer
Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
ADRIATIC study explored the benefits of immune maintenance therapy after LS-SCLC radiotherapy and chemotherapy. In the presence of immunotherapy, is it necessary to increase the dosage of radiotherapy and can it further improve…
- Trial name
- NCT06943235
- Testing
- Probiotics, concurrent Hyperfractionated Radiotherapy, Immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
The study is being conducted to evaluation of the Efficacy and Safety of QL1706 Combined with Chemotherapy Induction in Sequential Immunotherapy Consolidation After Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung…
- Conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy, Consolidation Immunotherapy
- Trial name
- NCT07091305
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Chest Hospital
Toripalimab, Surufatinib
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Based on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that…
- Conditions
- Toripalimab, Surufatinib, Chemoradiotherapy, Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Trial name
- NCT06719700
- Testing
- Chemotherapy, Immunotherapy, Angio-immuno kinase inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Lung Cancer, Small Cell, Limited-stage Small Cell Lung Cancer (LS-SCLC)
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Radiotherapy can activate local and systemic immune responses through a variety of mechanisms, which can enhance anti-tumor immune effects.
- Trial name
- NCT06914050
- Testing
- Adebrelimab, EC/EP, SBRT
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00062322
- Testing
- cisplatin, irinotecan hydrochloride, conventional surgery
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Limited-stage Small-cell Lung Cancer
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung…
- Trial name
- NCT07798947
- Testing
- SHR-7787 Injection, SHR-1316
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer
This is a single-arm, single-center, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. The study evaluates the effectiveness and safety of first-line treatment with benmelstobart (an…
- Trial name
- Aurora004 (NCT07538258)
- Testing
- Benmelstobart, Anlotinib, Cisplatin or carboplatin
- Volunteers
- 27 people
- Sponsor
- Yayi He
Limited-stage Small Cell Lung Cancer (LS-SCLC)
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
This study is a prospective, single-arm, multicenter, exploratory clinical trial. It aims to evaluate the efficacy and safety of tislelizumab combined with nintedanib as consolidation therapy for patients with limited-stage small…
- Trial name
- NCT07485920
- Testing
- Tislelizumab and nintedanib
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Qingdao University
SCLC, Limited Stage
Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
This is a retrospective, multi-centre, single arm study to assess the safety and efficacy of receiving Durvalumab in patients with Small Cell Lung Cancer Limited Stage (LS-SCLC) who have not progressed following sequential…
- Trial name
- NCT07309211
- Where
- 4 sites in China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University